These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8431007)

  • 1. Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
    Kort JJ; Bilello JA; Bauer G; Drusano GL
    Antimicrob Agents Chemother; 1993 Jan; 37(1):115-9. PubMed ID: 8431007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.
    Kageyama S; Hoekzema DT; Murakawa Y; Kojima E; Shirasaka T; Kempf DJ; Norbeck DW; Erickson J; Mitsuya H
    AIDS Res Hum Retroviruses; 1994 Jun; 10(6):735-43. PubMed ID: 8074936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.
    Bilello JA; Bilello PA; Prichard M; Robins T; Drusano GL
    J Infect Dis; 1995 Mar; 171(3):546-51. PubMed ID: 7876599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.
    Reedijk M; Boucher CA; van Bommel T; Ho DD; Tzeng TB; Sereni D; Veyssier P; Jurriaans S; Granneman R; Hsu A
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1559-64. PubMed ID: 7492104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
    Bilello JA; Bilello PA; Kort JJ; Dudley MN; Leonard J; Drusano GL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2523-7. PubMed ID: 8585738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.
    Otto MJ; Reid CD; Garber S; Lam PY; Scarnati H; Bacheler LT; Rayner MM; Winslow DL
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2606-11. PubMed ID: 8109924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
    Pagano PJ; Chong KT
    J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
    Lamarre D; Croteau G; Wardrop E; Bourgon L; Thibeault D; Clouette C; Vaillancourt M; Cohen E; Pargellis C; Yoakim C; Anderson PC
    Antimicrob Agents Chemother; 1997 May; 41(5):965-71. PubMed ID: 9145853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
    Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Connell EV; Hsu MC; Richman DD
    Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
    Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
    Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.
    Bechtold CM; Patick AK; Alam M; Greytok J; Tino JA; Chen P; Gordon E; Ahmad S; Barrish JC; Zahler R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):374-9. PubMed ID: 7726501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.
    Ojwang JO; Buckheit RW; Pommier Y; Mazumder A; De Vreese K; Esté JA; Reymen D; Pallansch LA; Lackman-Smith C; Wallace TL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2426-35. PubMed ID: 8585721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.
    Kageyama S; Weinstein JN; Shirasaka T; Kempf DJ; Norbeck DW; Plattner JJ; Erickson J; Mitsuya H
    Antimicrob Agents Chemother; 1992 May; 36(5):926-33. PubMed ID: 1510415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
    Borman AM; Paulous S; Clavel F
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():419-26. PubMed ID: 8601776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
    Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation.
    Babé LM; Craik CS
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2430-9. PubMed ID: 7840583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
    Rabin L; Hincenbergs M; Moreno MB; Warren S; Linquist V; Datema R; Charpiot B; Seifert J; Kaneshima H; McCune JM
    Antimicrob Agents Chemother; 1996 Mar; 40(3):755-62. PubMed ID: 8851606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.